Chemistry:Pynegabine
From HandWiki
Pynegabine (developmental code name HN37) is a Kv7.2 and Kv7.3 potassium channel opener which is under development for the treatment of epilepsy in China.[1][2][3] The drug is an analogue of flupirtine and retigabine (ezogabine).[2][3][4] However, it shows 55-fold greater potency in activating Kv7.2 channels and 127-fold greater potency in activating Kv7.3 channels compared to retigabine in vitro.[2] In addition, it shows improved chemical or metabolic stability compared to retigabine and in relation to this may have reduced toxicity in comparison.[2][3] The drug is under development by the Shanghai Institute of Materia Medica and Hainan Haiyao.[1][2][3] As of 2026, it is in phase 2 clinical trials for epilepsy.[1][2][3]
See also
- Retigabine
- Flupirtine
- Azetukalner
- Opakalim
References
- ↑ 1.0 1.1 1.2 "Delving into the Latest Updates on Pynegabine with Synapse". 7 March 2026. https://synapse.patsnap.com/drug/3adad2a5adef47b89081fc1625f59200.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Targeting Kv7 Potassium Channels for Epilepsy". CNS Drugs 39 (3): 263–288. March 2025. doi:10.1007/s40263-024-01155-3. PMID 39853501.
- ↑ 3.0 3.1 3.2 3.3 3.4 "Potassium channel agonists emerging as treatment options for focal epilepsy: are we breaking new ground?". Expert Opinion on Emerging Drugs: 1–8. May 2026. doi:10.1080/14728214.2026.2675274. PMID 42153277.
- ↑ "Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate". Journal of Medicinal Chemistry 64 (9): 5816–5837. May 2021. doi:10.1021/acs.jmedchem.0c02252. PMID 33929863.
 |  |
